LONDON (dpa-AFX) - BTG plc (BTG.L) reported that, on a constant currency basis, the business delivered double-digit revenue growth during the six months to 30 September 2016, in line with the Group's expectations. Specialty Pharmaceuticals has delivered a good performance across the portfolio.
BTG plc said its outlook for full year underlying revenue growth remains unchanged. On the basis of current foreign exchange rates, the Group now expects reported full year revenue to be ahead of its previously announced guidance range of 510 million-540 million pounds.
Louise Makin, BTG's CEO, said: 'We have had a strong first half, delivering double-digit constant currency revenue growth as we have continued to grow the business. The acquisition of Galil Medical has strengthened and diversified our interventional oncology portfolio, which also saw the US launch and approval in Canada of our innovative visible bead LC Bead LUMI. We anticipate further progress in the second half of the year, including the EU approval of DC Bead LUMI, completing the US PMA submission for the PneumRx Coil and the launch in Canada of Varithena.'
Copyright RTT News/dpa-AFX
© 2016 AFX News
